Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases

Journal of Medicinal Chemistry

Volumn 52, Issue 9, 2009, Pages 2776-2785

  Grolla, Ambra A ^a   Podestà, Valeria ^a   Chini, Maria Giovanna ^b   Di Micco, Simone ^b   Vallario, Antonella ^a   Genazzani, Armando A ^a   Canonico, Pier Luigi ^a   Bifulco, Giuseppe ^b   Tron, Gian Cesare ^a   Sorba, Giovanni ^a   Pirali, Tracey ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; N1 [1 [(1,1' BIPHENYL) 4 YLMETHYL] 2 OXO 2 [(2 PHENYLETHYL)AMINO]ETHYL] N8 HYDROXY N1 (PHENYLMETHYL)OCTANEDIAMIDE; N1 [2 (CYCLOHEXYLAMINO) 2 OXO 1 (PHENYLMETHYL)ETHYL] N7 HYDROXY N1 (PHENYLMETHYL)HEPTENEDIAMIDE; N1 HYDROXY N8 METHYL N8 [2 OXO 2 [(2 PHENYLETHYL)AMINO] 1 (PHENYLMETHYL)ETHYL]OCTANEDIAMIDE; UNCLASSIFIED DRUG; ZINC DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; LIPOPHILICITY; MOLECULAR DOCKING; MOLECULAR INTERACTION; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

BENZAMIDES; BINDING SITES; CARBOXYLIC ACIDS; CELL CYCLE; CELL LINE, TUMOR; CHELATING AGENTS; DRUG DESIGN; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; MODELS, MOLECULAR; PHENYLENEDIAMINES; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; ZINC;

EID: 65649124129     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801529c     Document Type: Article

References (25)

1. (a) Yoo, C. B.; Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discovery 2006, 5, 37-50.
2. (b) Bolden, J.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylases inhibitors. Nat. Rev. Drug Discovery 2006, 5, 769-784. (Pubitemid 44348499)
3. (a) Miller, T. A.; Witter, D. J.; Belvedere, S. Histone deacetylases inhibitors. J. Med. Chem. 2003, 46, 5097-5116.
4. (b) Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylases inhibitors: from bench to clinic. J. Med. Chem. 2008, 51, 1505-1529.
5. Marks, P. A.; Breslow, R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 2007, 25, 84-90. (Pubitemid 46087907)
6. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (London) 1999, 401, 188-193. (Pubitemid 29436325)
7. (a) Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Yoshida, M.; Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 87-92. (Pubitemid 32095868)
8. (b) Yoshida, M.; Furumai, R.; Nishiyama, M.; Komatsu, Y.; Nishino, N.; Horinouchi, S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 2001, 48, 20-26.
9. Komatsu, Y.; Tomizaki, K.; Tsukamoto, M.; Kato, T.; Nishino, N.; Sato, S.; Yamori, T.; Tsuruo, T.; Furumai, R.; Yoshida, M.; Horinouchi, S.; Hayashi, H. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res. 2001, 61, 4459-4466. (Pubitemid 32685775)
10. (a) Ugi, I.; Meyr, R.; Fetzer, U.; Steinbruckner, C. Versuche mit Isonitrilen. Angew. Chem., Int. Ed. Engl. 1959, 71, 386-388.
11. (b) Dömling, A.; Ugi, I. Multicomponent reactions with isocyanides. Angew. Chem., Int. Ed. Engl. 2000, 39, 3168-3210. (Pubitemid 46624001)
12. (a) Condorelli, F.; Gnemmi, I.; Vallario, A.; Genazzani, A. A.; Canonico, P. L. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br. J. Pharmacol. 2008, 153, 657-668.
13. (b) Pirali, T.; Pagliai, F.; Mercurio, C.; Boggio, R.; Canonico, P. L.; Sorba, G.; Tron, G. C.; Genazzani, A. A. Triazole-modified histone deacetylase inhibitors as a rapid route to drug discovery. J. Comb. Chem. 2008, 10, 624-627.
14. Mühlethaler-Mottet, A.; Meier, R.; Flahaut, M.; Bourloud, K. B.; Nardou, K.; Joseph, J. M. Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol. Cancer 2008, 7, 55. (Pubitemid 350160080)
15. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662. (Pubitemid 128590223)
16. (a) Wang, D.-F.; Wiest, O.; Helquist, P.; Lan-Hargest, H.-Y.; Wiech, N. L. On the function of the 14 Å long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. J. Med. Chem. 2004, 47, 3409-3417. (Pubitemid 38746091)
17. (b) Park, H.; Lee, S. Homology modeling, force field design, and free energy simulation studies to optimize the activities of histone deacetylase inhibitors. J. Comput.-Aided Mol. Des. 2004, 18, 375-388. (Pubitemid 40069136)
18. (c) Wang, D.-F.; Helquist, P.; Wiech, N. L.; Wiest, O. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J. Med. Chem. 2005, 48, 6936-6947. (Pubitemid 41533115)
19. (d) Maulucci, N.; Chini, M. G.; Di Micco, S.; Izzo, I.; Cafaro, E.; Russo, A.; Gallinari, P.; Paolini, C.; Nardi, M. C.; Casapullo, A.; Riccio, R.; Bifulco, G.; De Riccardis, F. Molecular insights into azumamide E histone deacetylases inhibitory activity. J. Am. Chem. Soc. 2007, 129, 3007-3012. (Pubitemid 46417978)
20. (e) Di Micco, S.; Terracciano, S.; Bruno, I.; Rodriquez, M.; Riccio, R.; Taddei, M.; Bifulco, G. Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modelled on the natural product FR235222. Bioorg. Med. Chem. 2008, 16, 8635-8642.
21. Stote, R. H.; Karplus, M. Zinc binding in proteins and solution: a simple but accurate nonbonded representation. Proteins 1995, 23, 12-31.
22. Breneman, C. M.; Wiberg, K. B. Determining atom-centered monopoles from molecular electrostatic potentials. The need for high sampling density in formamide conformational analysis. J. Comput. Chem. 1990, 11, 361-373.
23. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, J. A., Jr.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. Gaussian 03, revision E.01; Gaussian, Inc.: Wallingford, CT, 2004.
24. Sanner, M. F. Python: a programming language for software integration and development. J. Mol. Graphics Modell. 1999, 17, 57-61. (Pubitemid 30029318)
25. Sanner, M. F.; Olson, A. J.; Spehner, J. C. Reduced surface: an efficient way to compute molecular surfaces. Biopolymers 1996, 38, 305-320. (Pubitemid 126580771)